FibroGen
Ginny Kosor has over 20 years of management experience in various roles within the facilities and operations departments of clinical laboratory, medical device, and biological companies. Ginny has proven skills in team building, decision making, and troubleshooting. Currently, they are serving as the Executive Director of Facilities Operations at FibroGen, where they are responsible for overseeing the construction of a pilot facility in Beijing, China. Prior to joining FibroGen, Ginny worked as the Director of Facilities-Operations at Genitope and as an Associate Director Facilities-Operations at Avigen.
Ginny Kosor obtained a Bachelor of Science degree in Business Administration and Management, General from Chadwick University. The specific start and end years of their education are not provided.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.